Introducing Crowell & Moring’s Government Contractor Recovery Practice Performance Review Offering (PRO)
Client Alert | 1 min read | 03.16.17
The Government Contracts Group of Crowell & Moring LLP is pleased to announce its Government Contractor Recovery Practice, focused on recovery opportunities for our clients in in the government contracting industry. Our team consists of experienced and highly skilled attorney and non-attorney government contract management professionals who stand ready to assist clients with identifying and pursuing claims based on a variety of contractual theories – including REAs and claims to recover (i) increased performance costs attributable to Government action or delay, (ii) costs resulting from Government-initiated contract termination, (iii) costs of remediating certain environmental pollution and toxic tort litigation covered by certain indemnification clauses, and (iv) other costs to which contractors are entitled by operation of contract or statute. Our Performance Review Offering (PRO) allows, at your request, our team of experienced Crowell & Moring attorneys to provide a “diagnostic” review of the relevant documentation on your contract or program and make a recommendation regarding whether or not to pursue a claim; we can also discuss alternative fee arrangements, including risk-sharing, full and partial contingency arrangements.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
